COMMUNIQUÉS West-GlobeNewswire

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024

28/10/2024 - 13:00

Media Release SYDNEY, AUSTRALIA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for [...]

Inovalon Launches Seven New Software Solutions And Feature-Set Expansions To Drive Ever-Greater Impact Across the Healthcare Continuum

28/10/2024 - 13:00

Leading Cloud-Based SaaS Company Introduces New Products for Provider, Payer, Pharmacy, and Life Sciences Customers to Advance Data-Driven Healthcare BOWIE, Md., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Inovalon , a leading [...]

Soleno Therapeutics to Participate in Upcoming November Investor Conferences

28/10/2024 - 13:00

REDWOOD CITY, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]

Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)

28/10/2024 - 13:00

NEEDHAM, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL ), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]

Positive Preliminary Results Demonstrate Autonomix’s Proprietary RF Ablation Technology’s Ability to Reduce Opioid Use in Ongoing Human Clinical Trial

28/10/2024 - 13:00

100% of the responder group went to zero opioid use at 4-6 weeks post-procedure Up to 75% of late-stage pancreatic cancer patients are prescribed opioids and data suggests 20% are at risk for abuse and misuse 1 Data [...]

ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS

28/10/2024 - 13:00

AGOURA HILLS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its fourth publication of its TGFB2 series. Clinical data demonstrated that pancreatic cancer patients [...]

Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024

28/10/2024 - 12:00

BURLINGTON, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type [...]

Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024

28/10/2024 - 12:00

PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 8:30 a.m. ET [...]

Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024

28/10/2024 - 12:00

PITTSBURGH, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its third quarter 2024 financial results [...]

Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

28/10/2024 - 12:00

– ATEV™ demonstrated superiority at six and 12 months (co-primary endpoints) compared to autogenous fistula, the current standard of care for hemodialysis access – - ATEV also showed superior function and patency in [...]

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

28/10/2024 - 12:00

- DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a gain of +8.9 letters compared to baseline - – DURAVYU 2.7mg demonstrated an early and sustained anatomical improvement mirroring BCVA [...]

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

28/10/2024 - 12:00

Agreement expected to accelerate MRT-6160 clinical development and broadly explore therapeutic opportunities across multiple indications Monte Rosa to receive up-front payment of $150 million and is eligible to receive [...]

PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance

28/10/2024 - 12:00

SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in [...]

Amwell to participate in upcoming investor conferences

28/10/2024 - 12:00

BOSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leader in digital care, announced company leaders will participate in several upcoming investor conferences. Ido Schoenberg, M.D., Amwell chairman and [...]

Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority

28/10/2024 - 12:00

The Israel Innovation Authority will fund Pluri and BIRAD's collaboration to advance MAIT Cell Therapy, led by Professor Cyrille Cohen , Head of the laboratory of tumor immunology and immunotherapy at Bar-Ilan [...]

Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®

28/10/2024 - 12:00

Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing significant statistical improvement for GIMOTI over Oral Metoclopramide in All Cause Emergency [...]

Purespring Therapeutics presents new preclinical data on novel gene therapy for IgA Nephropathy at ASN Kidney Week 2024

28/10/2024 - 12:00

Results from the study underpin the potential of Purespring’s lead AAV gene therapy programme, PS-002, as an important novel modality to treat IgAN Data support progression towards a Phase I/II clinical trial London – [...]

Levicept to Present Phase II Data at ACR Convergence 2024

28/10/2024 - 10:00

Abstract selected for oral presentation at 8am EST on 19 November SANDWICH, United Kingdom, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class [...]

Aravax Completes Recruitment into Phase 2 Study of PVX108, a novel immunotherapy for the Treatment of Peanut Allergy

28/10/2024 - 10:00

MELBOURNE, Australia, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation immunotherapies designed to be safe, convenient, and precisely targeted, today announces [...]